Anti-Clotting Medication Apixaban To Get Expedited FDA Review.

The AP  (11/30) reports, "The Food and Drug Administration will give the Pfizer Inc. and Bristol-Myers Squibb Co. experimental anti-clotting drug apixaban [Eliquis] a priority review with the goal of making a decision on it by March 28." Both companies stated "that the FDA accepted an application for their drug to be used in the prevention of strokes and systemic embolism in patients with atrial fibrillation." Apixaban received approval from "the European Union in May for preventing blood clots in patients who have had hip or knee replacement surgery." Also covering the story are Reuters  (11/30, Sherman) and the Wall Street Journal  (11/30, B3, Loftus, Subscription Publication).